McGill

CSE Bulletin: New Listing - Prisma Capital Inc. (PCC)

Retrieved on: 
Friday, January 14, 2022 - 7:54pm

Toronto, Ontario--(Newsfile Corp. - Le 14 janvier/January 2021) - The common shares of Prisma Capital Inc. have been approved for listing on the CSE.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - Le 14 janvier/January 2021) - The common shares of Prisma Capital Inc. have been approved for listing on the CSE.
  • Prisma Capital Inc. is a resource exploration issuer that acquires and explores mineral properties.
  • Les actions ordinaires de Prisma Capital Inc. ont t approuves pour inscription la CSE.
  • Prisma Capital Inc. est un metteur d'exploration de ressources qui acquiert et explore des proprits minires.

LifeLabs welcomes four new members to its board of directors

Retrieved on: 
Monday, January 10, 2022 - 6:56pm

Toronto, Ontario, Jan. 10, 2022 (GLOBE NEWSWIRE) -- LifeLabs is pleased to share that four new individuals have joined its board of directors.

Key Points: 
  • Toronto, Ontario, Jan. 10, 2022 (GLOBE NEWSWIRE) -- LifeLabs is pleased to share that four new individuals have joined its board of directors.
  • The recently appointed board members possess a variety of exceptional experience and skills in the fields of health care, technology, and business operations.
  • We are proud to welcome these exceptionally qualified business leaders to the LifeLabs board of directors, says Charles Brown, LifeLabs President and CEO.
  • Board members play a pivotal role in overseeing LifeLabs strategic plan and governance, while also supporting its vision, purpose, strategic priorities, and values.

Sunshine Biopharma Announces $1,361,000 in Debt Reduction

Retrieved on: 
Wednesday, December 22, 2021 - 1:52pm

This debt conversion strengthens the financial condition of the Company and conserves the cash on hand for our ongoing research and development activities of our antiviral and anticancer drugs, said, Camille Sebaaly, CFO of Sunshine Biopharma.

Key Points: 
  • This debt conversion strengthens the financial condition of the Company and conserves the cash on hand for our ongoing research and development activities of our antiviral and anticancer drugs, said, Camille Sebaaly, CFO of Sunshine Biopharma.
  • Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4.
  • In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound.
  • Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

CORPORATE ADVISORY FIRM M3 PARTNERS ADDS DEBT AND RESTRUCTURING EXPERT JAVIER SCHIFFRIN AS MANAGING DIRECTOR

Retrieved on: 
Wednesday, December 15, 2021 - 1:30pm

NEW YORK, Dec. 15, 2021 /PRNewswire/ --M3 Partners, LP, ("M3") a leading independent corporate advisory firm, today announced that Javier Schiffrin has joined the firm's team of advisory, restructuring, turnaround and performance improvement veterans as Managing Director, effective immediately.Mr.

Key Points: 
  • NEW YORK, Dec. 15, 2021 /PRNewswire/ --M3 Partners, LP, ("M3") a leading independent corporate advisory firm, today announced that Javier Schiffrin has joined the firm's team of advisory, restructuring, turnaround and performance improvement veterans as Managing Director, effective immediately.Mr.
  • Schiffrin brings deep expertise in debt restructurings, having participated in complex financial transactions as a principal investor, investment banker and corporate lawyer.
  • Mo Meghji, founder and Managing Partner of M3, said, "Javier is an outstanding addition to our roster of senior professionals who provide the highest level corporate and financial expertise.
  • M3 is a leading, independent corporate advisory firm that provides operational, strategic, and financial solutions to a broad range of clients.

Andria Samis appointed Program Director of National Newspaper Awards

Retrieved on: 
Wednesday, December 8, 2021 - 4:38pm

TORONTO, Dec. 8, 2021 /CNW/ -The Board of Governors of the National Newspaper Awards (NNAs) is pleased to announce the appointment of Andria Samis as the organization's next Program Director, effective July 1, 2022.

Key Points: 
  • TORONTO, Dec. 8, 2021 /CNW/ -The Board of Governors of the National Newspaper Awards (NNAs) is pleased to announce the appointment of Andria Samis as the organization's next Program Director, effective July 1, 2022.
  • Samis joins Bev Wake, who earlier was appointed the NNAs' next Executive Director, also effective July 1.
  • "We are excited to have Andria join the program in the important role of program director," said Paul Samyn, Chair of the NNA Board of Governors.
  • This is the 72nd year of the awards program, which was established in 1949 to encourage excellence and reward achievement in daily newspaper work in Canada.

Cornerstone Specialty Wood Products' New Manufacturing Facility Nears Completion

Retrieved on: 
Wednesday, December 8, 2021 - 1:39pm

Located in a suburb of Louisville, Kentucky, the plant will enable Cornerstone to increase its manufacturing output to more than double its current capacity.

Key Points: 
  • Located in a suburb of Louisville, Kentucky, the plant will enable Cornerstone to increase its manufacturing output to more than double its current capacity.
  • "As a result of this tremendous growth, we are approaching the upper limits of our current production capacity.
  • This investment will ensure we are in position to deliver ResinDek products quickly to our valued customers well into the future."
  • ABOUT CORNERSTONE SPECIALTY WOOD PRODUCTS, LLC
    For more than 20 years, Cornerstone Specialty Wood Products, LLC ( www.resindek.com ) has been at the forefront of research and development in the field of engineered wood floor panels for the material handling industry.

Comrit Investments Nominates Highly Qualified and Independent Director Candidate for Election to New York City REIT’s Board of Directors

Retrieved on: 
Wednesday, December 1, 2021 - 2:00pm

Ms. Stern currently serves on the Board of Directors of Cedar Realty Trust, Inc. (NYSE: CDR), a publicly traded REIT specializing in grocer-anchored retail properties.

Key Points: 
  • Ms. Stern currently serves on the Board of Directors of Cedar Realty Trust, Inc. (NYSE: CDR), a publicly traded REIT specializing in grocer-anchored retail properties.
  • Comrit Investments 1, LP is an investment partnership that invests in income generating real estate through public non-traded real estate investment trusts.
  • Founded in 2015 and based in Tel Aviv, Washington D.C. and New York City, Comrit is sponsored by I.B.I.
  • Comrit Investments Ltd., as the general partner of Comrit, may be deemed the beneficial owner of the 267,520 shares of Class A Common Stock owned by Comrit.

Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results

Retrieved on: 
Thursday, November 18, 2021 - 9:05pm

NORTHBROOK, Ill., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today reported financial results for the third quarter of 2021.  

Key Points: 
  • ET
    NORTHBROOK, Ill., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today reported financial results for the third quarter of 2021.
  • We have achieved some exciting milestones this quarter, said Dr. Robert Dudley, President and Chief Executive Officer of Clarus and founder of its wholly-owned operating subsidiary, Clarus Therapeutics, Inc. JATENZO continues to grow in prescriptions with positive feedback from both patients and physicians.
  • - Third quarter 2021 total revenue increased 92.7% to $4.3 million from $2.2 million in the same period last year.
  • The following presents Clarus Therapeutics Holdings, Inc. statements of operations for the three and nine months ended September 30, 2021 and 2020:

Dyve Biosciences Hosting Key Opinion Leader Webinar on Gout and DYV702

Retrieved on: 
Monday, November 15, 2021 - 1:00pm

Webinar to be held Tuesday, November 23rd @ 11am ET

Key Points: 
  • Webinar to be held Tuesday, November 23rd @ 11am ET
    THOUSAND OAKS, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (Dyve), a clinical stage biotechnology company,today announced that it will host a key opinion leader (KOL) webinar on gout on Tuesday, November 23, 2021 at 11:00am Eastern Time.
  • Both experts will discuss the current treatment landscape for gout and unmet medical need in treating the pain, swelling, and discomfort associated with gout flares.
  • DYV702 demonstrated a statistically significant improvement in overall response rate, lower rescue medication use, and an improvement in physical function.
  • Dyves lead asset, DYV702,recently completed a 20-center, 100-patient, Phase 2 clinical study for the treatment ofpainassociated with acute gout.

Sunshine Biopharma Expands Board of Directors

Retrieved on: 
Wednesday, November 3, 2021 - 4:35pm

MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has expanded its board of directors from three to five and has appointed three new, independent directors.

Key Points: 
  • MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has expanded its board of directors from three to five and has appointed three new, independent directors.
  • We welcome them on board and look forward to calling on their expertise in our ongoing efforts to take the Company to new heights, said Dr. Steve Slilaty, CEO of Sunshine Biopharma.
  • Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4.
  • In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound.